The peroxisome proliferator-activated receptor (PPAR)-α activator, 5,8,11,14-eicosatetraynoic acid (ETYA), is an arachidonic acid analog. It is reported to inhibit up-regulation of pro-inflammatory genes. Among the inflammatory chemokines elaborated, glial cell-derived CCL2/MCP-1 is crucial, it promotes the migration and recruitment of inflammatory cells, it is primarily responsible for the initiation and progression of inflammatory responses in neurodegenerative disease and also associated with a variety of disease, including atherosclerosis.
ETYA has an anti-inflammatory mechanism, by increasing HuR-mediated-MKP-1 mRNA stability that leads to the specific suppression of CCL2/MCP-1 during inflammatory processes. Studies have shown that ETYA increases MKP-1 expression through HuR at the post-transcriptional level in a receptor-independent manner.?Thereby providing evidence that ETYA is a potential therapeutic modulator of inflammation. ETYA's influence on?suppressing CCL2/MCP-1 expression is an emerging therapeutic strategy for the treatment of neurodegenerative diseases such as?Alzheimer's disease, multiple sclerosis, and brain ischemia.
A recent research regarding upper aerodigestive cancer ( an aggressive malignancy) has revealed that PPARγ pathways would be a novel therapy for this cancer. ETYA is a PPARγ activator and results from this study have shown that it down regulates cell proliferation and has antineoplastic features.
?
BIOLEAF熱搜 BIOLEAF試劑盒 BIOLEAF ELISA BIOLEAF試劑 BIOLEAF品牌 BIOLEAF抗體 BIOLEAF耗材 BIOLEAF小儀器
sitemap 細(xì)胞庫(kù)查詢(xún) 危險(xiǎn)品圖標(biāo) 本公司網(wǎng)站所展示銷(xiāo)售的產(chǎn)品僅供科研！
滬公網(wǎng)安備 31011202007338號(hào)
